http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2022, Vol. 31 ›› Issue (5): 334-342.DOI: 10.5246/jcps.2022.05.029

• Short review • Previous Articles     Next Articles

Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia

Haiyan Wu1, Xiang Zhang1, Shanshan Ding1, Guohua Zhang1, Linlin Tang3, Lin Tang2,*()   

  1. 1 Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China
    2 Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
    3 Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang 261041, Shandong, China
  • Received:2021-09-24 Revised:2021-10-29 Accepted:2021-12-29 Online:2022-06-02 Published:2022-06-02
  • Contact: Lin Tang

Abstract:

The incidence of refractory mycoplasma pneumoniae pneumonia (RMPP) in children is increasing year by year, and the disease is progressing rapidly. It is accompanied by serious complications and legacy effects, seriously affecting the quality of life of children. The selection, dosage, and course of anti-MP drugs in children with RMPP have brought a lot of troubles to pediatric hospitals. In the present study, the characteristics, usage and dosage, drug resistance mechanism, and treatment progress of anti-MP drugs for the treatment of RMPP in children were reviewed. Collectively, our findings provided ideas for the treatment of children with RMPP using anti-MP drugs.

Key words: Children, Refractory mycoplasma pneumonia, Anti-mycoplasma drugs, Treatment, Progression

Supporting: